Fasenra for Eosinophilic granulomatosis with polyangiitis
Quick answer: Fasenra is used for Eosinophilic granulomatosis with polyangiitis as part of a anti-il-5 receptor monoclonal antibody treatment regimen. Humanized monoclonal antibody binding IL-5 receptor alpha to deplete eosinophils via ADCC The specific dosing for Eosinophilic granulomatosis with polyangiitis is determined by your prescriber based on individual factors.
Why is Fasenra used for Eosinophilic granulomatosis with polyangiitis?
Fasenra belongs to the Anti-IL-5 receptor monoclonal antibody class. Humanized monoclonal antibody binding IL-5 receptor alpha to deplete eosinophils via ADCC This action makes it useful for treating or managing Eosinophilic granulomatosis with polyangiitis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Fasenra is the right choice for a specific patient depends on the type and severity of Eosinophilic granulomatosis with polyangiitis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Eosinophilic granulomatosis with polyangiitis
Common adult dosing range: 30 mg subcutaneously every 4 weeks for 3 doses, then every 8 weeks. The actual dose for Eosinophilic granulomatosis with polyangiitis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Fasenra medicine page.
What to expect
Fasenra treatment for Eosinophilic granulomatosis with polyangiitis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Eosinophilic granulomatosis with polyangiitis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Fasenra is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Anti-IL-5 receptor monoclonal antibody for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Fasenra
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Fasenra full prescribing information · All Anti-IL-5 receptor monoclonal antibody alternatives
Frequently asked questions
How effective is Fasenra for Eosinophilic granulomatosis with polyangiitis?
Effectiveness varies by individual response, dose, and severity. Fasenra is one of several treatment options for Eosinophilic granulomatosis with polyangiitis, supported by clinical evidence within the anti-il-5 receptor monoclonal antibody class. Discuss expected response with your prescriber.
How long do I need to take Fasenra for Eosinophilic granulomatosis with polyangiitis?
Treatment duration depends on the nature of Eosinophilic granulomatosis with polyangiitis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Fasenra when used for Eosinophilic granulomatosis with polyangiitis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Fasenra for Eosinophilic granulomatosis with polyangiitis?
Yes. Multiple medicines and non-drug options exist for Eosinophilic granulomatosis with polyangiitis. Alternatives within the anti-il-5 receptor monoclonal antibody class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.